Felicitex Therapeutics Inc.

General Information
Business:

(Note: This is a unit IPO. Each unit consists of one share of common stock and one warrant to buy one share of common stock.)

We are a preclinical oncology drug development company focused on developing therapies targeting dormant and active cancer cells. We have designed and patented small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. This approach is lethal to cancer cells that rely on deregulation of the cell cycle for survival and has been shown to lead to the reversal of acquired resistance mechanisms. Our drug candidates are intended to be effective across a broad range of solid tumors and hematological cancers. We target a high unmet need in large oncology markets, including non-small cell lung cancer, or NSCLC, glioblastoma multiforme, or GBM, ovarian, prostate, colorectal, pancreatic cancers, and acute lymphoblastic leukemia, or ALL.

As an oncology drug development company, we are at the forefront of one of the most promising areas – dormant cancers. These cancers are responsible for resistance, metastasis, and recurrence. We are developing treatments that target both dormant and proliferating cancers to improve the effectiveness and long-term outcomes of treatments for the deadliest and most therapy resistant liquid and solid tumors: hematopoietic, ovarian, pancreatic, colorectal, osteosarcoma, glioblastoma, and lung.

We have created a pipeline of therapeutic compounds focused primarily on oncology indications of high unmet medical need. Our three most advanced product candidates are listed below:

 

  FX-1610, a small molecule inhibitor of DYRK1A and DYRK1B kinases (not orally bioavailable), is our compound being developed for pediatric leukemia – Acute Lymphoblastic Leukemia (ALL), an orphan drug indication of high unmet medical need. We expect to file an Investigational New Drug, or IND, application for FX-1610 during the first half of 2023.

 

  FX-7742 is our compound being developed for solid tumor indications including NSCLC and colorectal cancer with mutations in EGFR (such as T790M) and KRAS (such as G12C). We are targeting an IND submission for FX-7742 for NSCLC and/or other solid tumors with EGFR and KRAS mutations in the first half of 2023.
  FX-9847 is our compound being developed for solid tumor indications as a back-up to FX-7742, if FX-7742 fails safety testing. We expect to file an IND for FX-9847 in the second half of 2023, if we replace FX-7742 with FX-9847, or otherwise in the first half of 2024 assuming the required funds are available for this IND at that time.

(Note: Felicitex Therapeutics set terms for its IPO – 2.48 million units at $5.25 to $7.25 per unit to raise $15.5 million, in its S-1/A dated Sept. 16, 2022. Felicitex Therapeutics filed its S-1 on Aug. 10, 2022.)

Industry: Pharmaceuticals
Employees: 3
Founded: 2012
Contact Information
Address 27 Strathmore Road Natick, MA 01760
Phone Number (919) 213-0025
Web Address https://www.felicitex.com/
View Prospectus: Felicitex Therapeutics Inc.
Financial Information
Market Cap $43.38mil
Revenues $0 mil (last 12 months)
Net Income $-1.63 mil (last 12 months)
IPO Profile
Symbol FLCT
Exchange NASDAQ
Shares (millions): 2.5
Price range $5.25 - $7.25
Est. $ Volume $15.5 mil
Manager / Joint Managers Aegis Capital Corp.
CO-Managers
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change